George Letsas's Books

1. Major depressive disorder and treatment-resistant depression. 1.1. Major depressive disorder. 1.2. Treatment-resistant depression (TRD). 1.3. Demographic and clinical risk factors for resistant depression -- 2. Monoaminergic-based strategies : "Single-acting" agents. 2.1. Monoamine precursors for depression. 2.2. Selective serotonin reuptake inhibitors (SSRIs). 2.3. Serotonin receptor antagonists and agonists. 2.4. Serotonin reuptake enhancers. 2.5. [symbol]-2 adrenergic receptor agonists and antagonists. 2.6. Norepinephrine reuptake inhibitors (NRIs). 2.7. Selective [symbol] adrenergic receptor agonists. 2.8. Dopamine-selective agents -- 3. Monoaminergic-based strategies : "Dual-acting" agents. 3.1. Tricyclic antidepressants (TCAs). 3.2. Serotonin-norepinephrine reuptake inhibitors (SNRIs). 3.3. 5HT-2 and [symbol]-2 adrenergic receptor antagonists. 3.4. Norepinephrine-dopamine reuptake inhibitors -- 4. Monoaminergic-based strategies : "Triple-acting " agents. 4.1. Monoamine oxidase inhibitors (MAOIs). 4.2. Serotonin-norepinephrine-dopamine reuptake inhibitors. 4.3. Catechol-O-methyltransferase (COMT) inhibitors -- 5. Polypharmacy from the onset of treatment. 5.1. Adjunctive treatment with monoaminergic agents. 5.2. Adjunctive treatment with neuroendocrine agents. 5.3. Other agents -- 6. Polypharmacy strategies for treatment-resistant depression. 6.1. Adjunctive treatment with monoaminergic agents. 6.2. Adjunctive treatment with neuroendocrine agents. 6.3. Other agents -- 7. Monotherapy strategies for resistant depression. 7.1. Increasing the dose of antidepressants. 7.2. Switching antidepressants due to lack of efficacy -- 8. Non-pharmacologic approaches for resistant depression. 8.1. Device-based therapies. 8.2. Psychotherapy. 8.3. Exercise. 8.4. Yoga and meditation -- 9. Pharmacotherapy of relapse/recurrence prevention and treatment. 9.1. Antidepressant continuation and maintenance therapy studies. 9.2. Special topics in the pharmacotherapy of relapse prevention. 9.3. Treatment of depressive relapse/recurrence -- 10. Pharmacologic strategies to enhance antidepressant tolerability. 10.1. Adjunctive therapy. 10.2. Switching antidepressants due to intolerance -- 11. Agents operating on non-monoaminergic neurotransmitter systems. 11.1. GABA-ergic treatments. 11.2. Glycine and glutamate-based treatments. 11.3. Agents with combined GABA-ergic and glutamatergic activity. 11.4. Other anticonvulsants. 11.5. Neurokinin-receptor antagonists. 11.6. Nicotinic receptor-based treatments. 11.7. Cannabinoids and endocannabinoids. 11.8. Opioidergic therapies. 11.9. Other neurotransmitter systems -- 12. Neuroendocrine-based agents. 12.1. Hypothalamic-pituitary-gonadal axis (HPG). 12.2. Hypothalamic-pituitary-adrenal axis (HPA). 12.3. Hypothalamic-pituitary-thyroid axis (HPT). 12.4. Melatonin and melatonergic agents. 12.5. Other hormones -- 13. Metabolic-based and other agents. 13.1. Metabolic-based agents. 13.2. Agents with unknown mechanism of action -- 14. Biological predictors, moderators, and mediators of efficacy. 14.1. Definition and significance of mediators of outcome. 14.2. Genetic markers. 14.3. Neurophysiology. 14.4. Molecular biology

Book's by George Letsas

Philosophical Foundations of Contract Law

Philosophical Foundations of Contract Law

Current Legal Problems 2010

Current Legal Problems 2010

Pharmacotherapy for Depression and Treatment-resistant Depression

Pharmacotherapy for Depression and Treatment-resistant Depression

Philosophical Foundations of Contract Law

Philosophical Foundations of Contract Law

Username

Password

Username

Password

Password again

Birthday

Email